ru

Все / NYSE / NUVB.US

Nuvation Bio

Nuvation Bio

Инвестируйте без комиссии

Покупайте и продавайте дробные акции всего за €1

1Д
1Н
1М
3М
1Г
MAX

Информация и статистика

Изменения за день
1Д-100,00 %
3М-100,00 %
1Н-100,00 %
6М-100,00 %
1М-100,00 %
1Г-100,00 %
СИМВОЛ
NUVB
РЫНОК
NYSE
ISIN
US67080N1019

Дата

Закрыть

Изменение

Изменение (%)

Открыть

Высокий

Низкий

5,980,284,68 %5,706,045,65
5,760,162,78 %5,605,905,58
5,560,081,44 %5,485,605,30
5,330,193,56 %5,145,375,08
5,12-0,02-0,39 %5,145,285,02
5,140,101,95 %5,045,194,85
4,920,061,22 %4,865,224,85
4,760,224,62 %4,544,834,44
4,58-0,34-7,42 %4,924,984,49
4,93-0,18-3,65 %5,115,674,54
4,80-0,09-1,87 %4,894,984,74
4,82-0,28-5,81 %5,105,174,69
5,170,468,9 %4,715,434,71
4,72-0,12-2,54 %4,844,884,57
4,90-0,08-1,63 %4,985,004,66
4,960,234,64 %4,735,034,70
4,780,071,46 %4,714,814,59
4,75-0,02-0,42 %4,774,824,61
4,740,030,63 %4,715,054,65
4,69-0,10-2,13 %4,794,814,60
4,72-0,12-2,54 %4,844,924,61
4,790,438,98 %4,364,864,34
4,510,255,54 %4,264,604,21
4,240,081,89 %4,164,304,05
4,21-0,14-3,33 %4,354,424,16
4,32-0,34-7,87 %4,664,694,23
4,72-0,20-4,24 %4,924,924,64
4,780,000 %4,784,894,67
4,840,081,65 %4,764,904,63
4,760,030,63 %4,734,894,71
4,79-0,06-1,25 %4,854,924,67
4,81-0,21-4,37 %5,025,134,69
5,040,071,39 %4,975,184,78
4,830,5110,56 %4,324,874,10
4,41-0,10-2,27 %4,514,864,37
4,490,081,78 %4,414,564,35
4,45-0,01-0,22 %4,464,514,30
4,34-0,15-3,46 %4,494,514,19
4,56-0,04-0,88 %4,604,644,44
4,56-0,28-6,14 %4,845,174,51
4,89-0,13-2,66 %5,025,154,74
5,04-0,07-1,39 %5,115,254,96
5,12-0,14-2,73 %5,265,305,05
5,11-0,03-0,59 %5,145,275,00
5,120,081,56 %5,045,204,86
5,080,203,94 %4,885,124,82
4,81-0,04-0,83 %4,854,894,59
4,82-0,06-1,24 %4,884,934,74
4,850,122,47 %4,734,944,69
4,700,142,98 %4,564,774,51
4,60-0,04-0,87 %4,644,674,36
4,630,194,1 %4,444,684,42
4,53-0,32-7,06 %4,854,854,43
4,510,153,33 %4,364,554,22
4,45-0,07-1,57 %4,524,664,41
4,410,010,23 %4,404,624,39
4,510,132,88 %4,384,614,36
4,290,173,96 %4,124,324,11
4,05-0,19-4,69 %4,244,334,02
4,25-0,19-4,47 %4,444,604,18
4,420,153,39 %4,274,494,23
4,38-0,06-1,37 %4,444,504,33
4,280,040,93 %4,244,384,19
4,35-0,08-1,84 %4,434,504,17
4,22-0,04-0,95 %4,264,394,12
4,260,102,35 %4,164,344,09
4,28-0,08-1,87 %4,364,394,22
4,40-0,14-3,18 %4,544,584,31
4,50-0,08-1,78 %4,584,654,41
4,44-0,01-0,23 %4,454,594,28
4,37-0,10-2,29 %4,474,474,28
4,59-0,04-0,87 %4,634,754,50
4,69-0,07-1,49 %4,764,844,63
4,730,265,5 %4,474,814,41
4,590,051,09 %4,544,754,40
4,57-0,05-1,09 %4,624,744,44
4,740,255,27 %4,494,814,23
4,36-0,37-8,49 %4,734,844,13
5,840,183,08 %5,665,895,50
5,910,264,4 %5,655,955,61
5,800,223,79 %5,585,845,46
5,56-0,17-3,06 %5,735,825,49
5,640,061,06 %5,585,785,33
5,460,071,28 %5,395,645,29
5,440,020,37 %5,425,615,32
5,48-0,30-5,47 %5,785,795,39
5,77-0,02-0,35 %5,796,025,67
5,880,244,08 %5,645,975,64
5,77-0,10-1,73 %5,876,075,68
5,79-0,01-0,17 %5,805,915,48
5,720,172,97 %5,555,775,46
5,71-0,01-0,18 %5,725,895,59
5,64-0,20-3,55 %5,845,945,28
5,70-0,19-3,33 %5,896,155,65
5,62-0,22-3,91 %5,846,165,57
5,860,030,51 %5,836,035,48
5,900,264,41 %5,645,965,53
5,630,417,28 %5,225,655,18
5,24-0,05-0,95 %5,295,405,09
5,340,000 %5,345,415,20
5,30-0,28-5,28 %5,585,665,24
5,610,050,89 %5,565,755,52
5,50-0,03-0,55 %5,535,625,42
5,59-0,37-6,62 %5,966,015,52
5,91-0,28-4,74 %6,196,275,83
6,150,050,81 %6,106,275,87
6,010,376,16 %5,646,115,58
5,85-0,33-5,64 %6,186,275,79
6,14-0,30-4,89 %6,446,496,03
6,31-0,28-4,44 %6,596,646,18
6,55-0,02-0,31 %6,576,596,04
6,46-1,19-18,42 %7,657,676,29
8,04-0,38-4,73 %8,428,557,99
8,45-0,25-2,96 %8,708,878,33
8,840,333,73 %8,519,118,51
8,49-0,16-1,88 %8,658,718,37
8,590,080,93 %8,518,648,01
8,58-0,39-4,55 %8,979,068,26
8,960,091 %8,879,158,86
8,94-0,13-1,45 %9,079,088,82
9,06-0,21-2,32 %9,279,458,85
9,40-0,12-1,28 %9,529,579,23
9,520,060,63 %9,469,589,18
9,340,000 %9,349,549,05
9,54-0,01-0,1 %9,559,789,38
9,440,454,77 %8,999,548,98
8,990,343,78 %8,659,098,55
8,52-0,09-1,06 %8,618,888,38
8,660,222,54 %8,448,838,11
8,510,141,65 %8,378,578,22
8,430,293,44 %8,148,577,98
8,270,212,54 %8,068,537,95
7,84-0,02-0,26 %7,868,077,78
8,00-0,48-6 %8,488,837,97
8,58-0,16-1,86 %8,748,988,41
8,550,202,34 %8,358,728,12
8,310,060,72 %8,258,598,08
8,370,657,77 %7,728,407,53
7,47-0,44-5,89 %7,917,957,42
7,88-0,01-0,13 %7,898,057,73
8,03-0,05-0,62 %8,088,167,89
8,010,182,25 %7,838,267,79
7,880,455,71 %7,437,957,31
7,410,334,45 %7,087,516,98
6,990,030,43 %6,967,176,50
7,01-0,17-2,43 %7,187,526,82
7,152,1730,35 %4,987,374,94
4,800,153,12 %4,654,974,56
4,67-0,16-3,43 %4,834,944,59
4,860,306,17 %4,565,364,53
4,69-0,20-4,26 %4,894,974,63
4,93-0,07-1,42 %5,005,184,80
4,980,418,23 %4,575,044,50
4,64-0,22-4,74 %4,864,894,53
4,73-0,11-2,33 %4,845,034,44
5,020,122,39 %4,905,204,77
4,920,265,28 %4,665,024,49
4,83-0,32-6,63 %5,155,153,89
5,17-0,22-4,26 %5,395,395,08
5,220,132,49 %5,095,355,04
5,150,020,39 %5,135,425,08
5,26-0,14-2,66 %5,405,565,08
5,370,305,59 %5,075,475,00
5,040,112,18 %4,935,144,79
4,850,438,87 %4,424,894,40
4,390,081,82 %4,314,424,06
4,15-0,02-0,48 %4,174,343,89
4,210,5312,59 %3,684,243,64
3,700,246,49 %3,463,733,43
3,41-0,09-2,64 %3,503,643,33
3,63-0,19-5,23 %3,823,863,56
3,770,184,77 %3,593,823,49
3,55-0,12-3,38 %3,673,673,48
3,68-0,12-3,26 %3,803,803,57
3,74-0,02-0,53 %3,763,823,52
3,750,020,53 %3,733,833,62
3,720,102,69 %3,623,823,59
3,66-0,11-3,01 %3,773,793,49
3,770,030,8 %3,743,903,62
3,71-0,04-1,08 %3,753,853,64
3,71-0,01-0,27 %3,723,773,57
3,70-0,01-0,27 %3,713,853,50
3,700,3710 %3,333,973,28
3,220,020,62 %3,203,333,12
3,200,195,94 %3,013,282,97
3,01-0,15-4,98 %3,163,232,97
3,240,020,62 %3,223,423,15
3,22-0,01-0,31 %3,233,323,14
3,270,030,92 %3,243,323,12
3,220,000 %3,223,323,12
3,17-0,17-5,36 %3,343,483,12
3,260,010,31 %3,253,423,19
3,270,144,28 %3,133,433,06
3,15-0,05-1,59 %3,203,233,05
3,14-0,19-6,05 %3,333,373,06
3,350,092,69 %3,263,473,21
3,32-0,02-0,6 %3,343,433,24
3,35-0,19-5,67 %3,543,543,23
3,49-0,31-8,88 %3,803,853,17
3,900,4210,77 %3,484,103,46
3,420,236,73 %3,193,513,12
3,150,165,08 %2,993,212,97
2,95-0,01-0,34 %2,963,052,89
2,970,041,35 %2,933,012,85
2,92-0,04-1,37 %2,963,102,87
2,95-0,06-2,03 %3,013,072,87
2,980,113,69 %2,873,052,84
2,88-0,01-0,35 %2,893,012,80
2,900,155,17 %2,753,012,73
2,740,020,73 %2,722,872,66
2,710,082,95 %2,632,752,54
2,69-0,24-8,92 %2,932,952,64
2,900,113,79 %2,792,942,69
2,750,000 %2,752,872,69
2,760,134,71 %2,632,792,56
2,610,2810,73 %2,332,732,31
2,320,062,59 %2,262,352,18
2,24-0,09-4,02 %2,332,352,15
2,30-0,11-4,78 %2,412,562,26
2,340,010,43 %2,332,522,18
2,350,020,85 %2,332,392,22
2,370,083,38 %2,292,422,24
2,310,062,6 %2,252,342,19
2,23-0,04-1,79 %2,272,352,19
2,360,041,69 %2,322,482,31
2,41-0,09-3,73 %2,502,582,32
2,46-0,05-2,03 %2,512,602,39
2,550,031,18 %2,522,782,49
2,500,000 %2,502,602,43
2,510,000 %2,512,632,44
2,560,166,25 %2,402,602,33
2,350,010,43 %2,342,432,29
2,35-0,06-2,55 %2,412,512,29
2,300,031,3 %2,272,422,21
2,240,020,89 %2,222,352,17
2,230,062,69 %2,172,322,12
2,13-0,03-1,41 %2,162,252,05
2,14-0,10-4,67 %2,242,262,03
2,20-0,10-4,55 %2,302,312,14
2,31-0,05-2,16 %2,362,422,22
2,370,208,44 %2,172,452,12
2,05-0,06-2,93 %2,112,172,00
2,080,031,44 %2,052,182,00
2,090,062,87 %2,032,141,98
2,050,094,39 %1,962,091,87
1,94-0,02-1,03 %1,962,001,84
1,95-0,06-3,08 %2,012,121,92
1,93-0,05-2,59 %1,982,051,90
1,970,126,09 %1,852,001,78
1,88-0,14-7,45 %2,022,051,83
2,05-0,02-0,98 %2,072,162,00
2,030,062,96 %1,972,051,89
1,970,031,52 %1,942,031,81
1,790,126,7 %1,671,841,55
1,71-0,15-8,77 %1,861,871,68
1,860,158,06 %1,711,911,55
1,73-0,06-3,47 %1,791,831,66
1,81-0,37-20,44 %2,182,251,77
2,20-0,34-15,45 %2,542,741,95
2,530,000 %2,532,672,45
2,51-0,03-1,2 %2,542,552,40
2,48-0,08-3,23 %2,562,632,43
2,48-0,01-0,4 %2,492,562,36
2,45-0,02-0,82 %2,472,552,40
2,450,093,67 %2,362,482,25
2,340,166,84 %2,182,402,13
2,12-0,12-5,66 %2,242,282,08
2,26-0,01-0,44 %2,272,302,15
2,20-0,02-0,91 %2,222,372,10
2,24-0,14-6,25 %2,382,442,20
2,300,093,91 %2,212,362,14
2,250,198,44 %2,062,291,97
2,03-0,16-7,88 %2,192,231,98
2,17-0,12-5,53 %2,292,332,07
2,300,083,48 %2,222,412,19
2,260,041,77 %2,222,312,17
2,240,073,13 %2,172,282,09
2,17-0,04-1,84 %2,212,252,07
2,19-0,01-0,46 %2,202,252,08
2,15-0,10-4,65 %2,252,272,07
2,09-0,02-0,96 %2,112,172,00
2,10-0,12-5,71 %2,222,321,95
2,04-0,07-3,43 %2,112,161,97
2,09-0,35-16,75 %2,442,442,05
2,38-0,09-3,78 %2,472,542,35
2,460,124,88 %2,342,562,29
2,270,031,32 %2,242,322,17
2,250,156,67 %2,102,302,10
2,180,020,92 %2,162,222,07
2,160,041,85 %2,122,232,10
2,130,041,88 %2,092,162,05
2,130,062,82 %2,072,172,03
2,08-0,08-3,85 %2,162,252,02
2,060,073,4 %1,992,131,95
1,980,052,53 %1,932,071,87
1,970,042,03 %1,932,021,86
1,88-0,19-10,11 %2,072,081,79
2,020,031,49 %1,992,071,92
2,020,020,99 %2,002,101,89
1,990,199,55 %1,802,061,70
1,750,000 %1,751,801,60
1,790,137,26 %1,661,861,58
1,66-0,25-15,06 %1,911,921,60
1,800,2413,33 %1,561,851,51
1,66-0,01-0,6 %1,671,711,54
1,66-0,03-1,81 %1,691,771,61
1,790,042,23 %1,751,881,69
1,75-0,02-1,14 %1,771,811,64
1,76-0,01-0,57 %1,771,801,66
1,82-0,05-2,75 %1,871,901,77
1,870,010,53 %1,861,931,82
1,88-0,06-3,19 %1,941,991,82
1,94-0,04-2,06 %1,982,071,88
1,960,000 %1,962,001,82
1,89-0,05-2,65 %1,941,961,83
1,96-0,01-0,51 %1,972,011,87
1,98-0,03-1,52 %2,012,011,87
1,96-0,13-6,63 %2,092,091,90
2,09-0,10-4,78 %2,192,192,01
2,14-0,12-5,61 %2,262,332,09
2,21-0,02-0,9 %2,232,322,06
2,24-0,10-4,46 %2,342,442,16
2,290,4318,78 %1,862,371,79
1,880,031,6 %1,851,951,76
2,020,115,45 %1,912,091,77
1,890,010,53 %1,881,921,77
1,870,158,02 %1,721,921,68
1,820,021,1 %1,801,861,67
1,82-0,27-14,84 %2,092,221,77
1,970,010,51 %1,962,041,86
1,97-0,02-1,02 %1,992,091,93
1,98-0,09-4,55 %2,072,131,94
2,05-0,03-1,46 %2,082,111,95
2,08-0,14-6,73 %2,222,242,05
2,21-0,09-4,07 %2,302,352,17
2,27-0,05-2,2 %2,322,332,22
2,300,010,43 %2,292,372,26
2,32-0,01-0,43 %2,332,392,23
2,27-0,07-3,08 %2,342,382,23
2,290,041,75 %2,252,352,22
2,280,114,82 %2,172,342,14
2,23-0,01-0,45 %2,242,342,19
2,28-0,12-5,26 %2,402,432,24
2,38-0,05-2,1 %2,432,442,26
2,410,000 %2,412,472,35
2,45-0,02-0,82 %2,472,502,32
2,410,062,49 %2,352,452,22
2,270,020,88 %2,252,382,20
2,31-0,07-3,03 %2,382,512,26
2,40-0,04-1,67 %2,442,562,35
2,420,000 %2,422,532,38
2,45-0,04-1,63 %2,492,512,36
2,50-0,06-2,4 %2,562,602,38
2,52-0,27-10,71 %2,792,842,47
2,770,051,81 %2,722,842,59
2,650,114,15 %2,542,742,53
2,580,041,55 %2,542,692,48
2,51-0,09-3,59 %2,602,632,44
2,54-0,03-1,18 %2,572,632,45
2,60-0,06-2,31 %2,662,782,47
2,59-0,01-0,39 %2,602,642,47
2,67-0,01-0,37 %2,682,732,43
2,78-0,12-4,32 %2,903,012,70
3,01-0,28-9,3 %3,293,292,89
3,250,319,54 %2,943,472,94
Смотреть больше

Показанные данные относятся к периоду 07 янв. 2025 г. – 23 июн. 2026 г..
Изменения, открытия, закрытия, максимальные и минимальные значения основаны на ежедневной цене покупки NUVB.

Похожие обсуждения

MikePetrov

4 дня назад

Two Months In: Strong Growth From Nuvation Bio and Caris Life Sciences

For the past two months, I've been invested in Nuvation Bio and Caris Life Sciences. Their stock prices have performed very well.

Moc

5 месяцев назад

NUVB reported preliminary net product revenue of $24.7 million for IBTROZI since launch

Nuvation Bio Inc. (NUVB) reported preliminary net product revenue of $24.7 million for IBTROZI since its launch in June 2025, with fourth quarter revenue reaching $15.7 million. The company said 432 patients started treatment on IBTROZI for advanced ROS1-positive non-small cell lung cancer since the drug’s launch, with 216 new patients beginning treatment in the fourth quarter. The treatment adoption rate is approximately six times greater than prior ROS1 tyrosine kinase inhibitor launches based on IQVIA data, according to the company. Nuvation Bio received a $25 million milestone payment from Nippon Kayaku in the fourth quarter following establishment of a reimbursement price in Japan. The company reported preliminary cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025. On January 11, 2026, the company entered an exclusive license and collaboration agreement with Eisai Co., Ltd. to develop, register and commercialize taletrectinib for ROS1-positive non-small cell lung cancer in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. IBTROZI received FDA approval on June 11, 2025, for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer following Priority Review and Breakthrough Therapy designations. The company plans to continue enrollment of its phase 3 study evaluating safusidenib in high-grade and high-risk IDH1-mutant gliomas and pursue business development opportunities to expand its pipeline. The preliminary financial results are subject to adjustment pending completion of the company’s financial closing procedures. Nuvation Bio expects to issue full financial results for the fourth quarter and full year 2025 in March 2026.

Moc

7 месяцев назад

Good news

$NUVB announced the publication of positive Phase 2 study results for safusidenib in treating grade 2 IDH1-mutant glioma patients. The findings were published in the journal Neuro-Oncology on November 8. The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had received no prior anticancer therapy except for resection or biopsy. The trial met its primary endpoint with an objective response rate of 44.4%. At 24 months, 87.9% of patients remained progression-free. Median progression-free survival had not been reached as of the March 10, 2023 data cutoff, with a median follow-up time of 28 months. The median duration of response could not be estimated because no progression events had occurred. Adverse events were described as mostly mild to moderate. Grade 3 or greater treatment-related adverse events occurred in five patients (18.5%). Three patients discontinued treatment due to adverse events, two of which investigators considered related to safusidenib. The company noted that a Good Clinical Practice noncompliance issue regarding adverse event collection was identified during the study. Safety data was subsequently re-investigated and re-collected according to study protocol. Safusidenib is an oral, brain-penetrant inhibitor of mutant IDH1. Nuvation Bio is progressing the ongoing G203 study in high-grade IDH1-mutant gliomas, with a protocol amendment planned to finalize the study as a global Phase 3 trial to support potential regulatory approvals. The company stated that as of September 15, 2025, 12 patients remained on treatment with safusidenib. Gliomas are the most common type of brain cancer in adults, with nearly 2,400 people diagnosed with IDH1-mutant gliomas annually in the United States.

BailyW

7 месяцев назад

Up?

Has this got anymore juice? Holding nicely. What do people think?

Эта страница может содержать созданный группой контент, за который Trading 212 не несет ответственности. Всегда проводите собственные исследования. Trading 212 предоставляет услуги только по исполнению и не предлагает инвестиционные консультации или управление портфолио.

Связанные инструменты

Bank of New York Mellon

+19,95 (+15,64 %)

First Western Financial

+4,21 (+15,89 %)

Grab

-0,40 (-10,47 %)

Hercules Capital

+0,29 (+1,94 %)

Burford Capital

-0,17 (-3,90 %)

Credit Acceptance

+130,02 (+27,95 %)

Jasper Therapeutics

-0,3300 (-41,13 %)

NewtekOne

+1,54 (+12,53 %)

Better Home & Finance Holding

-6,10 (-18,63 %)

Coincheck Group

+0,33 (+19,41 %)

Invesco Mortgage Capital

-0,61 (-7,24 %)

GCM Grosvenor

+2,37 (+24,38 %)

Инвестирование без комиссии для всех

Покупайте и продавайте Nuvation Bio Inc +0,21 $ (3,65 %) и более 13 000 мировых акций и ETF

Могут применяться другие сборы. Ознакомьтесь с нашими условиями и тарифами.

phone

Покупайте акции мгновенно

Выберите свою любимую компанию

Выберите сколько инвестировать

Получите акции в считанные секунды

Создание богатства – это привычка.
Автоматизируйте ее с помощью пая.

Инвестируйте в готовые паи или создавайте свои собственные, выбирая из тысяч акций и ETF

Подробнее

Подробнее

Смотреть видео

Становитесь владельцами самых дорогих акций, таких как Google, Amazon и Apple

Смотреть видео

Flag fr

Euronext
Paris

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

Лондонская фондовая биржа

Flag pt

Euronext Лиссабон

Flag fr

Euronext
Paris

Flag us

NYSE,
NASDAQ

Flag de

Xetra,
Gettex

Flag nl

Euronext Amsterdam

Flag es

Bolsa
de Madrid

Flag at

Wiener
Börse

Flag uk

Лондонская фондовая биржа

Flag pt

Euronext Лиссабон

Смотреть все торговые инструменты

Поддержка клиентов 24/7

Среднее время ответа - 29 секунд

Начните создавать богатство сейчас

Станьте одним из 5 миллионам пользователей

Получить приложение

Открыть счёт

Получите мобильное приложение

qr-code

Все представленные статистические данные являются глобальными. Количество клиентов представляет собой количество финансируемых Счетов.

Отлично

Оценка 4,6 / 5 на основании 95 591 обзоров на

Trustpilot

Оценка 4,6 / 5 на основании 95 591 обзоров на

Trustpilot

Приглашен(-а)

Love the Trading 212 App it’s great fun…

Love the Trading 212 App it’s great fun to use and it’s really intuitive in helping you to monitor your investments as they grow!

Richard Knights

4 дня (дней) назад

Приглашен(-а)

Safe,simple and easy

Great website, easy to use. Regular updates. Sit back and do nothing. Couldn’t be simpler. Very happy.

Nigel

4 дня (дней) назад

Приглашен(-а)

Great app and easy to use

The Trading 212 app is easy to use and I like the fact you can see your investment grow on a daily basis.

Hazel

4 дня (дней) назад

Приглашен(-а)

Very easy account making/saving…

It’s been so easy to create accounts and start investing/saving would recommend to anyone

BLaw

4 дня (дней) назад

Приглашен(-а)

Best app

This investment app is very easy to use and has a user-friendly interface. I feel confident knowing my money is secure, and the investment process is simple and straightforward. The customer support is also responsive and helpful whenever needed. Highly recommended for anyone looking for a reliable investment platform!

Teesside Customer

4 дня (дней) назад

Приглашен(-а)

Easy and stress free

Investing is made very easy with Trading 212.

HMN

4 дня (дней) назад

Приглашен(-а)

Easy to use

Easy to set up easy to use deposit and take out

Mr S Axford

4 дня (дней) назад

Приглашен(-а)

The best trading app out there

The best trading app out there. No question

Paul

4 дня (дней) назад

Приглашен(-а)

Easy to use

Easy to use. I love it

Mark White

4 дня (дней) назад

Приглашен(-а)

Low fees ETFs + on of the best interest…

Low fees ETFs + on of the best interest rate on cash attached

Pavel Voronkin

4 дня (дней) назад

Приглашен(-а)

Easy to use

Easy to use, recommend if you’re interested in investing

Ben

4 дня (дней) назад

Приглашен(-а)

Very helpful and professional and my…

Very helpful and professional and my query was dealt with quickly and efficiently.

Mrs Mazzotta

4 дня (дней) назад

Приглашен(-а)

All good!

Till now, almost a year after start using it, the experience has been going very well. No issues with any of the activities I needed to perform, friendly user interface and enough tools. I'm also glad that looks like the team ears the community. Keep up the good work.

Hugo Valadas

4 дня (дней) назад

Приглашен(-а)

A great platform to invest

A great platform to invest. The app is easy to navigate. Easy to transfer money.

Simon C

4 дня (дней) назад

Used stocks and shares ISA as well as…

Used stocks and shares ISA as well as Cash ISA. Like the stocks interface, info about financials of the companies. It does not work very reliably on niche stocks or ETFs, but I would be surprised if it did. Also it tracks the ISA limits, ISAs are flexible. So can take money in and out all the time. Withdrawals are very quick. They tell it may take few businesses days, but usually goes through in a few minutes (if not seconds). Cash ISA interest was high, not it is not really, but I suppose it is a price for ability to withdraw anytime. It would be nice if I could buy government bonds there as stocks and shares ISA product.

Ruslan Lytvynov

5 дня (дней) назад

Приглашен(-а)

Great experience.

Orders execution is really smooth, level of transparency is amazing when it comes to clear track of transactions and pies is very helpful. If they just can enable higher freedom when it comes to communication between members in one community/pie, it will be amazing.

ahmed elsayes

5 дня (дней) назад

Приглашен(-а)

Great app

Great app. Very easy to use. No complications atall

customer

5 дня (дней) назад

Приглашен(-а)

Great even for beginners

Really easy to use and track investments. Fees are clear and fair. The ability to communicate with other investors for support is a good feature, especially for beginners. I'm a newbie to stocks and shares, this app has been perfect to learn with as well as actual investments.

Paul Carr

5 дня (дней) назад

Приглашен(-а)

T212 - The SIPP’er heros.

The Trading 212 team pretty much does all the heavy lifting when setting up a SIPP, you do need to supply the obvious details, and will most likely need to respond to your previous pension provider to confirm your sure with the transfer. But as far as pension pot transfers go, T212 is fantastic! They looked into potential loss of protected terms and brought this up quickly for me to make a decision. The response time from the team is really quick and professional- I cant recommend them enough. I also really like the SIPP interface on the app, its really easy to understand and is seamless with your other investment accounts. 10/10.

Thomas Warren

5 дня (дней) назад

Приглашен(-а)

Great site makes investing very easy…

Great site makes investing very easy and exciting, still a little confused on some things but getting there, thanks

Mr Cursons

5 дня (дней) назад

Показаны некоторые положительные отзывы наших клиентов

Наши награды

Часто задаваемые вопросы

Какова цена акций Nuvation Bio (NUVB)?

Текущая цена Nuvation Bio (NUVB) составляет 5,97 $.

Каков 52-недельный максимум NUVB?

52-недельный максимум для NUVB составляет 9,78 $.

Каков 52-недельный минимум NUVB?

52-недельный минимум для NUVB составляет 1,78 $.

Какова недельная эффективность NUVB?

За последнюю неделю цена NUVB изменилась на 16,6 %.

Какова ежемесячная эффективность NUVB?

За последний месяц цена NUVB изменилась на 26,48 %.

Какова доходность NUVB за 3 месяца?

За последние три месяца цена NUVB изменилась на 41,47 %.

Какова доходность NUVB за 6 месяцев?

За последние шесть месяцев цена NUVB изменилась на -37,42 %.

Какова годовая эффективность NUVB?

За последний год цена NUVB изменилась на 203,05 %.